November 06, 2018 - Spaulding Clinical Research, LLC, a global clinical pharmacology, cardiac safety and biometrics solutions provider, announces the U.S. Food and Drug Administration (FDA) performed a routine inspection related to a specific clinical trial conducted in 2017. On the fifth and final day, the FDA auditor concluded that no observations or findings were identified and that all clinical trial results were well-organized and well-documented.
This is Spaulding Clinical’s first inspection for 2018 and this 5-Day FDA inspection is a great testament to the company’s investments in quality and talent.
November 6-7 | Boston, MA // Booth #75
Connect with Us on LinkedIn through the banner below:
With the most advanced technology; the integration of monitoring, recording, analyzing and reporting all in one place; and a unique specialization in cardiac safety testing for new drugs in development, we provide the highest quality results with the most accurate data and the most efficient procedures in the industry.
At Spaulding Clinical Research, we hold ourselves to the highest standards. Passionate in our pursuit of ingenious solutions that save time and money for our clients and heroic in our ambitions to ensure the health and safety of patients, Spaulding Clinical Research strives to be the Phase I facility by which all others are measured.